Marksans Pharma Q4 Results 2024

Marksans Pharma

Marksans Pharma, a notable pharmaceutical company, is an Indian company with headquarters in Mumbai. The company is expertized in creating and promoting a diverse range of pharmaceutical blends. Vascular, diabetic, and antibiotic therapy are among the many therapeutic areas covered by the company's broad product portfolio. Marksans Pharma is committed to quality and follows international regulations. It has a license from the US Food and Drug Administration and other international health regulatory agencies. By leveraging its state-of-the-art research and development as well as production capabilities in India and other locations, Marksans Pharma strives to offer affordable and effective healthcare solutions to people worldwide.

Marksans Pharma Q4 Results 2024

Marksans Pharma released the fourth quarter of 2024 financial results. The company made Rs 78.29 crore in profit, a 4.4% decrease from Rs 81.93 crore during the same time the previous year. The company's income from operations increased by 15.2% to Rs 560.01 crore from Rs 485.98 crore the previous year, despite the drop in profit. For the quarter, Rs 109.6 crore was the earnings before interest, taxes, depreciation, and amortization, or EBITDA.

There was a total of Rs 576.54 crore in revenue and Rs 476.27 crore in costs during the quarter. In addition, Marksans Pharma declared a final dividend of Rs 0.60 per equity share for the financial year 2023–2024. This payment will be distributed within 30 days of the approval of the upcoming Annual General Meeting (AGM).

The company's managing director, Mark Saldanha, expressed satisfaction with the results, citing a 35% rise in EBITDA and an 18% year-over-year improvement in operating revenue, which were driven by the introduction of new products, gains in market share, lower costs of raw materials, and improved operational efficiency. The company also exceeded its annual revenue goal of Rs 2000 crore.

Marksans Pharma made large construction expenditures at its sites in Teva, Goa, the US, and the UK in addition to investing Rs 34.6 crore in research and development. The company's business in the US and North America rose by 18.5% to Rs 918.1 crore; its business in the UK and Europe grew by 22.9% to Rs 943 crore; its business in Australia and New Zealand grew by 4.4% to Rs 218.8 crore; and its business in the rest of the world reported revenue of Rs 97.4 crore.

Marksans Pharma Q4 Results 2024 Date

On May 30, 2024, Marksans Pharma released its Q4 financial results for the fiscal year 2023–2024. The business posted strong financial results, with both revenue and earnings growing significantly. The company's excellent financial health and dedication to generating shareholder value were demonstrated by the board's approval of the audited financial results, which included a proposed final dividend. The findings are accessible on the company website and were released in compliance with SEBI standards.

To know more details about Marksans Pharma Q4 Results 2024 [Click Here]

Marksans Pharma Q4 Results Consolidated Statement

Here is the consolidated profit and loss statement for Marksans Pharma